Exocrine pancreatic insufficiency.
EPI in dogs represents a well-defined condition that can now be diagnosed simply by the analysis of a single serum sample for TLI. A low TLI concentration represents a highly sensitive and specific test for EPI and may also predict the development of disease before the onset of clinical signs. A lack of pancreatic enzymes results in interference with degradation of the major dietary constituents, and there are secondary changes in the small intestine including a decreased synthesis of enterocyte proteins; bacterial overgrowth in the proximal intestine (SIBO); and malabsorption of vitamins, including cobalamin. Management with uncoated pancreatic extract and a low-fat, high-quality protein diet fed in small, divided meals should be effective in most cases. In animals showing a poor response, additional treatment may be necessary with long-term oral antibiotic for SIBO and H2-receptor blockers before a meal to inhibit acid secretion and minimize degradation of pancreatic extract. Diagnosis of the relatively rare cases of EPI in cats is best achieved by analysis of fecal trypsin by the use of specific substrates until a TLI test becomes readily available, and management should follow similar principles to those established for dogs. The major question for the future is the underlying cause of pancreatic acinar atrophy in dogs, particularly the relative importance of genetic and environmental factors. This information may allow detection and elimination of a genetic abnormality by selective breeding or prophylactic treatment that would prevent the development of the disease.
Batt
R M
RM
Department of Small Animal Medicine and Surgery, Royal Veterinary College, University of London, Hertfordshire, England.
D000818:Animals; D004283:Dog Diseases / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D004285:Dogs; D010188:Exocrine Pancreatic Insufficiency / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000628:therapy / Q000662:veterinary*; D007410:Intestinal Diseases / Q000209:etiology / Q000378:metabolism / Q000382:microbiology / Q000662:veterinary*; D010184:Pancreatic Extracts / Q000627:therapeutic use*; D012680:Sensitivity and Specificity; D014362:Trypsinogen / Q000097:blood*
D010184:Pancreatic Extracts; D014362:Trypsinogen